Clinical Trial Update: A Safety Study of NNZ-2566 in Patients With Rett Syndrome [Phase 2]

View source ↗

Summary

Phase 2 safety study of NNZ-2566 in Rett syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Rett Syndrome | Phase 2 | Status: COMPLETED